These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1385624)

  • 1. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
    Beal MF; Matson WR; Storey E; Milbury P; Ryan EA; Ogawa T; Bird ED
    J Neurol Sci; 1992 Mar; 108(1):80-7. PubMed ID: 1385624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
    Beal MF; Matson WR; Swartz KJ; Gamache PH; Bird ED
    J Neurochem; 1990 Oct; 55(4):1327-39. PubMed ID: 2144582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
    Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
    Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
    Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
    Front Immunol; 2022; 13():997240. PubMed ID: 36263032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases.
    Jauch D; Urbańska EM; Guidetti P; Bird ED; Vonsattel JP; Whetsell WO; Schwarcz R
    J Neurol Sci; 1995 May; 130(1):39-47. PubMed ID: 7650530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease.
    Sorgdrager FJH; Vermeiren Y; Van Faassen M; van der Ley C; Nollen EAA; Kema IP; De Deyn PP
    J Neurochem; 2019 Dec; 151(5):656-668. PubMed ID: 31376341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
    Guidetti P; Luthi-Carter RE; Augood SJ; Schwarcz R
    Neurobiol Dis; 2004 Dec; 17(3):455-61. PubMed ID: 15571981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
    Stoy N; Mackay GM; Forrest CM; Christofides J; Egerton M; Stone TW; Darlington LG
    J Neurochem; 2005 May; 93(3):611-23. PubMed ID: 15836620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan metabolites and brain disorders.
    Stone TW; Mackay GM; Forrest CM; Clark CJ; Darlington LG
    Clin Chem Lab Med; 2003 Jul; 41(7):852-9. PubMed ID: 12940508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in kynurenic acid in Huntington's disease motor cortex.
    Connick JH; Carlà V; Moroni F; Stone TW
    J Neurochem; 1989 Mar; 52(3):985-7. PubMed ID: 2521895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.
    Miranda AF; Boegman RJ; Beninger RJ; Jhamandas K
    Neuroscience; 1997 Jun; 78(4):967-75. PubMed ID: 9174065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease.
    Ellison DW; Beal MF; Martin JB
    Brain Res; 1987 Aug; 417(2):389-92. PubMed ID: 2958109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenine metabolism in Alzheimer's disease.
    Baran H; Jellinger K; Deecke L
    J Neural Transm (Vienna); 1999; 106(2):165-81. PubMed ID: 10226937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K; Robotka H; Toldi J; Vécsei L
    J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
    Ostapiuk A; Urbanska EM
    CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
    Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
    Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease.
    Ellison DW; Beal MF; Mazurek MF; Malloy JR; Bird ED; Martin JB
    Brain; 1987 Dec; 110 ( Pt 6)():1657-73. PubMed ID: 2892568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.